SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : Investing in Exponential Growth
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Paul H. Christiansen6/11/2017 1:25:39 AM
   of 1084
 
Crispr May Cure All Genetic Disease—One Day



Jennifer Doudna was sitting in her UC Berkeley office when she got the first call from a reporter asking what she thought about scientists using Crispr to modify embryos. At the time, the embryos in question were monkeys. It was late 2014, and Doudna was just beginning to become the face of Crispr/Cas9—the bacterial enzyme behind today’s gene editing revolution. Since then she has fielded an ongoing avalanche of questions about the implications of her discovery. How it’s going to change the future of everything from medicine to agriculture to energy production. But inevitably the questions always get around to super-babies.

Today, at WIRED’s 2017 Business Conference in New York, it took just a few minutes. Doudna said it was exactly this possibility—Crispr custom-designed human offspring—that made her take a step back from her own research and get involved in public discussions around the technology. For the last few years she’s been speaking to scientists, politicians, and federal regulators around the world about the potential risks and rewards of Crispr. “I think it’s really likely that in the not-too-distant future it will cure genetic disease,” she said. “But globally we need to come up with a consensus on moving forward in a responsible way.”

wired.com

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News